Key facts
- It has raised $14.2M; the latest was Later Stage VC ($14.2M) in Jan 2026.
- Notable investors include Jolmo Investment, Xingxiang Investment Holding Group, Zero2IPO Venture Capital, Zhangjiagang Industrial Capital Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Biosynthetica (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosynthetica (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosynthetica (Biotechnology)
Manufacturer of advanced microbial engineering technologies intended to create nucleotide-related raw materials and active pharmaceutical ingredients through synthetic biology. The company offers genetically optimized microorganisms and metabolic engineering platforms, enabling pharmaceutical, nutraceutical, and chemical industries to achieve sustainable production with reduced costs and improved efficiency.
- Sector
- Healthcare
- HQ
- Jiangsu, China
- Founded
- 2014
- Website
- smicrobe.com/
- Ownership
- Privately Held (backing)
Biosynthetica (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosynthetica (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosynthetica (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.